DaVita, one of the largest dialysis providers in the United States, reported that its average revenue per treatment edged lower in the second quarter. The company attributed the decline to a shift in its patient mix, as more patients moved off Affordable Care Act (ACA) plans after the expiration of pandemic-era subsidies.
The Colorado-based company said revenue per treatment fell to $415.87 from $417.59 a year earlier. While the decline is modest, it highlights a broader trend that investors are watching closely: how changes in health insurance coverage affect reimbursement rates for medical services.
Why the payer mix matters
Dialysis is a life-sustaining treatment for people with kidney failure, and the vast majority of DaVita's revenue comes from insurance reimbursements. The amount DaVita receives for each treatment depends on the type of insurance a patient has. Commercial plans typically pay more than government programs like Medicare or Medicaid, and ACA marketplace plans can fall somewhere in between.
During the pandemic, the federal government provided enhanced subsidies for ACA plans, making them more affordable for many people. Those subsidies expired, and as a result, some patients have dropped their ACA coverage. When patients leave ACA plans, they may move to other types of coverage—such as Medicaid or Medicare—that reimburse at lower rates. This shift in the "payer mix" can drag down the average revenue per treatment, even if the total number of treatments stays steady.
DaVita also pointed to softer sales of certain medications and supplies used in its clinics, which can further weigh on per-treatment revenue.
Profit beat and 2026 outlook
Despite the revenue-per-treatment dip, DaVita managed to beat Wall Street's profit expectations for the quarter. The company did not provide specific earnings figures in its release, but the beat suggests that cost controls or other factors helped offset the reimbursement pressure.
DaVita also reaffirmed its outlook for 2026, signaling that management expects the current trends to continue without a major deterioration. That reassurance helped calm investors who might have worried that the ACA subsidy expiration would hit the company harder.
What it means for investors
For everyday investors, the key takeaway is that DaVita's business is sensitive to changes in health policy and insurance dynamics. The company's revenue per treatment is a closely watched metric because it reflects how much DaVita gets paid for its core service. A decline, even a small one, can signal that reimbursement pressure is building.
However, the fact that DaVita beat profit estimates and kept its 2026 guidance intact suggests that the company is managing the headwinds. Investors often look at whether a company can maintain its earnings trajectory even when revenue metrics soften.
DaVita's situation is not unique. Other healthcare providers that rely on government or ACA reimbursements have faced similar challenges as pandemic-era policies unwind. For example, Match's revenue outlook disappoints in a different sector, but the principle is the same: when a key revenue driver weakens, investors pay attention.
Looking ahead, investors will likely monitor DaVita's patient volumes, reimbursement rates, and any changes in health policy that could affect the payer mix. The company's ability to maintain its profit margins will be crucial, especially if the trend of patients leaving ACA plans continues.
Broader context
DaVita operates in a highly regulated industry, and its fortunes are tied to government programs like Medicare, which covers most dialysis patients. The company has long argued that reimbursement rates for dialysis are too low, and it has lobbied for higher payments. The recent dip in revenue per treatment could add fuel to that argument.
For investors, it's worth remembering that DaVita's stock has been a solid performer over the years, but it can be volatile in response to policy news. The company's reaffirmed 2026 outlook provides some stability, but the underlying reimbursement pressures are unlikely to disappear overnight.
As always, it's important to consider how a company like DaVita fits into a diversified portfolio. Healthcare is a defensive sector, but individual stocks can still face company-specific risks. The key is to stay informed about the factors that drive revenue and profitability.
In the coming quarters, watch for updates on DaVita's payer mix and any commentary from management about the impact of ACA subsidy expiration. The company's next earnings report will show whether the trend is stabilizing or accelerating.
